Polish obesity drug makers spend millions on doctor collaborations amid reimbursement push

Pharmaceutical companies producing obesity drugs spent 25 million zł in 2025 on collaborations with Polish doctors, experts, and patient groups, funding educational campaigns. This spending coincides with pending reimbursement applications that could cost the state budget 1.4 billion zł over several years. The disclosure raises questions about the influence of industry funding on medical opinion and policy decisions in Poland.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works